Semaglutide vs Ozempic vs Wegovy: What’s the Difference?
Ozempic, Wegovy, and Rybelsus are FDA-approved pharmaceutical products built on the same active molecule — semaglutide — each cleared under a separate regulatory submission for a different indication. AminoForge’s research-grade version of this molecule is cataloged as Single Regulator (SIA-31-C18) — a laboratory reagent for in vitro and preclinical GLP-1 receptor research, not a substitute for or version of any approved drug.
What Is Semaglutide, Mechanistically?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a 31-amino acid peptide engineered to mimic and extend the activity of the endogenous incretin hormone GLP-1. It carries approximately 94% sequence homology to native human GLP-1, with an Aib substitution and a C18 fatty diacid side chain that extends its plasma half-life to roughly 7 days by promoting albumin binding and resisting DPP-4 degradation. For the full mechanistic research overview, see Semaglutide Research.
Semaglutide Research Identity
| Primary Research Name | Semaglutide |
| AminoForge Catalog Listing | Single Regulator (SIA-31-C18) |
| Receptor Class | GLP-1 receptor monoagonist |
| Amino Acid Count | 31 |
| CAS Number | 910463-68-2 |
| PubChem CID | 56843331 |
| Molecular Formula | C₁₁₄₄H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4,113.58 g/mol |
| Primary Research Area | GLP-1 receptor pharmacology and incretin signaling |
Three Approved Products, One Molecule
Ozempic, Wegovy, and Rybelsus are all FDA-approved pharmaceutical products containing semaglutide as the active ingredient, manufactured by Novo Nordisk under pharmaceutical GMP conditions for use in human patients under medical supervision. Each was cleared through a separate regulatory submission for a distinct approved indication, and each uses a different delivery format determined through that regulatory process. They are categorically different from a research compound: they are finished drug products intended for clinical use, not laboratory reagents.
Research-grade semaglutide is not an alternative form or delivery method of any of these three products. It is a laboratory research chemical, chemically related to the same active molecule, supplied strictly for in vitro and preclinical research use.
Research-Grade Material vs. Approved Pharmaceutical Products
Research-grade semaglutide sold under RUO designation shares the same core peptide sequence and C18 fatty-diacid modification studied in the published pharmacology literature on this molecule. The distinction that matters is regulatory status and intended use: FDA-approved products have completed the full clinical trial and manufacturing quality process required for approved human pharmaceutical use. Research-grade material has not, and is sold exclusively as a laboratory reagent for in vitro and preclinical investigation — not for human or animal administration.
Single Regulator (SIA-31-C18) is AminoForge’s catalog listing for this research compound — ≥99% purity by HPLC, independent third-party COA on every batch.
Research-grade Single Regulator (SIA-31-C18), independently tested.
Why Researchers Use Research-Grade Material
Research-grade GLP-1 receptor agonists are used to investigate receptor pharmacology, downstream signaling cascades, and comparative receptor studies alongside Dual Regulator and Triple Regulator in cell and animal models. The published mechanistic literature on this receptor class is extensive and continues to grow. For the broader mechanistic landscape, see Tirzepatide vs Semaglutide.
These are laboratory research applications used to investigate receptor pharmacology and signaling mechanisms. Findings from in vitro, preclinical, or other laboratory research models do not establish a use, benefit, or outcome in humans or animals.
The GLP-1 Research Landscape Beyond Semaglutide
Semaglutide is a GLP-1 receptor monoagonist — the reference standard for GLP-1-specific research. Understanding where it sits among the newer multi-receptor research compounds helps contextualize study design:
- Single Regulator (SIA-31-C18) — GLP-1R monoagonist. Reference standard for GLP-1 pathway research. Available at AminoForge.
- Dual Regulator (DIA-39-C20) — GLP-1R + GIPR dual agonist research compound. Available at AminoForge. See Tirzepatide vs Mounjaro vs Zepbound.
- Triple Regulator (TIA-39-C20) — GLP-1R + GIPR + GCGR research compound. Available at AminoForge. See Retatrutide vs Ozempic vs Mounjaro.
- Amylin Analog (CAG-31-C18) — amylin receptor pathway, complementary to GLP-1 for combination-protocol research. Available at AminoForge.
FAQ
Is research-grade semaglutide the same product as Ozempic or Wegovy?
No. Ozempic and Wegovy are FDA-approved pharmaceutical products manufactured for human patients under medical supervision. AminoForge’s Single Regulator (SIA-31-C18) is a research-only laboratory reagent, not an approved drug, alternative formulation, or substitute for either.
Why do Ozempic and Wegovy have different names if it’s the same active molecule?
Each is a separately regulated pharmaceutical product, cleared through its own approval pathway for a distinct indication.
What purity should research-grade semaglutide have?
Look for a COA showing ≥99% purity by HPLC with mass-spectrometry-confirmed molecular weight. See our COA verification guide.
Is Single Regulator approved for human or animal use?
No. It is for research use only (RUO) and has not been evaluated by the FDA or any equivalent body for any medical, diagnostic, or clinical use in humans or animals.
Further Reading
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.